Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Type of study
Language
Year range
1.
Chinese Journal of Internal Medicine ; (12): 233-238, 2021.
Article in Chinese | WPRIM | ID: wpr-885148

ABSTRACT

Objective:To analyze the epidemiological characteristics of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients in Beijing and investigate the associated factors.Methods:The clinical data of patients with HIV infection who were treated in HIV/AIDS designated hospitals (Peking Union Medical College Hospital, Beijing Ditan Hospital and Beijing Youan Hospital) were retrospectively analyzed.Results:A total of 11 572 patients were finally included in the study, among whom 532 patients (4.6%) were co-infected with HIV and HBV. Most of the co-infected patients were young male adults (28~48 years old), accounting for 85.9%. The main transmission route was homosexual behavior (74.8%). There were 87.4% co-infected patients treated with two anti-HBV drugs, including lamivudine (3TC) and tenofovir (TDF). From 2013 to 2018, the annual prevalence of HIV and HBV co-infection decreased gradually, with the rate of 6.37%, 4.55%, 3.92%, 4.68%, 4.24% and 2.74%, respectively. In our study, The main influencing factors of HIV and HBV co-infection were age older than 28 years old versus<28 years old ( OR=2.807, 95% CI 1.241-6.345) and marriage status (married versus unmarried, OR=1.259, 95% CI 1.004-1.579). Conclusions:The proportion of HBV infection in HIV-infected patients is 4.60% (532) in our cohort. From 2013 to 2018, the prevalence of HIV and HBV co-infection in Beijing shows a decreasing trend. The risk of co-infection is higher in married young adults (28~48 years old).

2.
International Journal of Pediatrics ; (6): 427-430, 2014.
Article in Chinese | WPRIM | ID: wpr-454115

ABSTRACT

Objective To investigate the changes of cytokines in hand-foot-and-mouth disease( HFMD) patients.Methods Retrospective analysis was performed on the clinical data of 262 cases of HFMD.All 262 children with HFMD were divided into two groups:severe cases and non-severe cases.Five cytokines( IL-2,IL-6,IL-10,TNF-αand IFN-γ) simultaneously were detected by luminex multiplexed assays.Results There were 153 severe cases and 109 non-severe cases,The results showed that the levels of IL-2,IL-6,IL-10,TNF-αin severe cases were higher than non-severe cases,and the differences were significant (18.02 ng/L vs 22.71ng/L, 28.42 ng/L vs 53.76 ng/L,17.92 ng/L vs 42.37 ng/L,102.29 ng/L vs 207.99 ng/L,P0.05).In 40 critical cases,plasma levels of IL-2,IL-6,IL-10,TNF-α,and IFN-γwere significantly decreased after administration of intravenous immunoglobulin( P<0.05 ) .Conclusion Some cytokines increase in children with severe HFMD, indicating that inflammatory and anti-inflammatory reaction may play importent roles in the pathogenesis of se-vere HFMD.The findings suggest that intravenous immunoglobulin might play a therapeutic role in severe HFMD.

3.
Chinese Journal of Postgraduates of Medicine ; (36): 12-13, 2012.
Article in Chinese | WPRIM | ID: wpr-433498

ABSTRACT

Objective To investigate clinical features and treatment experience of severe cases of influenza A H 1N 1.Methods A retrospective analysis of 78 severe cases of influenza A H1N1 admitted in Beijing You'an Hospital from June 2009 to January 2010 were performed.Clinical manifestations,laboratory tests and imaging characteristics were summarized and discussed.Results The mean value of incubation period of severe cases was 2.1 days (range 1-7 days).The main clinical manifestations were fever,red throat and cough,mostly complicated with pneumonia.The mortality is higher in the elders and patients with underlying diseases.Chest X-ray showed unilateral or bilateral patchy shadows in lungs.Conclusion Severe influenza A H1N1 is a dangerous illness with high mortality.Close attention should be paied to the elder and patients with underlying diseases.It is important to take antiviral treatment in time.

SELECTION OF CITATIONS
SEARCH DETAIL